Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years

Journal of Urology

Volumn 172, Issue 5 I, 2004, Pages 1865-1870

  Wirth, Manfred P ^a   See, William A ^b   McLeod, David G ^b   Iversen, Peter ^b   Morris, Tom ^b   Carroll, Kevin ^b  

^a UNIVERSITY OF DRESDEN MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

Androgen antagonists; Prostatic neoplasms

Indexed keywords

BICALUTAMIDE; PLACEBO;

ABDOMINAL PAIN; ACCIDENT; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FLU LIKE SYNDROME; FOLLOW UP; GYNECOMASTIA; HEADACHE; HEALTH PROGRAM; HEMATURIA; HERNIA; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; INFECTION; INJURY; MAJOR CLINICAL STUDY; MALE; MASTALGIA; PELVIS PAIN SYNDROME; PHARYNGITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RASH; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; WEIGHT GAIN;

EID: 5444248630     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000140159.94703.80     Document Type: Article

References (21)

1. Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer, 80: 764, 1997
2. Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., Kattan, M. W. and Scardino, P. T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167: 528, 2002
3. Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F. and Fine, J.: Long-term survival among men with conservatively treated localized prostate cancer. JAMA, 274: 626, 1995
4. Smith, J. A., Jr., Soloway, M. S. and Young, M. J.: Complications of advanced prostate cancer. Urology, suppl., 54: 8, 1999
5. See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D. et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
6. Carroll, K. J.: On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials, 24: 682, 2003
7. Iversen, P., Johansson, J.-E., Lodding, P., Lukkarinen, O., Lundmo, P., Klarskov, P. et al: Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curvative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol, 172: 1871, 2004
8. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R. O. et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet, 360: 103, 2002
9. Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E. et al: Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys, 49: 937, 2001
10. Pilepich, M. V., Winter, K., Lawton, C., Krisch, R. E., Wolkov, H., Movsas, B. et al: Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Proc Am Soc Clin Oncol, 22: 381, abstract 1530, 2003
11. Hanks, G. E., Lu, J., Machtay, V., Venkatesan, V., Pinover, W., Byhardt, R. et al: RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol, 19: 327a, 2000
12. Messing, E., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D. and Trump, D.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol, suppl., 169: 396, abstract 1480, 2003
13. Hanks, G. E., Pajak, T. F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V. et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol, 21: 3972, 2003
14. Granfors, T., Modig, H., Damber, J.-E. and Tomic, R.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol, 159: 2030, 1998
15. Kirby, R.: Treatment options for early prostate cancer. Urology, 52: 948, 1998
16. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z. and Stratte, P. T.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 163: 181, 2000
17. Iversen, P., Melezinek, I. and Schmidt, A.: Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU Int, 87: 47, 2001
18. Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., Van Poppel, H., Tammela, T. L. J. et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164: 1579, 2000
19. Sieber, P. R., Keiller, D. L., Kahnoski, R. J., Gallo, J. and McFadden, S.: Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol, 171: 2272, 2004
20. Payne, H., Tyrrell, C., Tammela, T., Bakke, A., Lodding, P., Goedhals, L. et al: Prophylactic breast irradiation significantly reduces the incidence of bicalutamide ('Casodex')-induced gynecomastia. Int J Radiat Oncol Biol Phys, 54: 135, abstract 230, 2002
21. Saltzstein, D., Cantwell, A., Sieber, P., Ross, J. R., Silvay-Mandeau, O. and Gallo, J.: Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU Int, suppl., 90: 120, abstract PD-4.07, 2002